Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

abstract：:There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...

journal_title：Hematological oncology

authors： Hojo H,Morimura Y,Abe M,Tominaga K,Nozawa Y,Nakamura N,Ono N,Tasaki K,Yamaguchi Y,Suzuki S

更新日期：1992-11-01 00:00:00

abstract：:Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...

journal_title：Hematological oncology

authors： Wolach O,Fraser A,Luchiansky M,Shapiro C,Radnay J,Shpilberg O,Lishner M,Lahav M

更新日期：2015-03-01 00:00:00

abstract：:Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...

journal_title：Hematological oncology

authors： Barbui T,Bassan R,Chisesi T,Battista R,Cortelazzo S,Rodeghiero F,Capnist G,D'Emilio A,Viero P,Dini E

更新日期：1985-01-01 00:00:00

abstract：:Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

journal_title：Hematological oncology

authors： Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

更新日期：2020-10-01 00:00:00

abstract：:The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

journal_title：Hematological oncology

authors： Cotter FE

更新日期：1997-02-01 00:00:00

abstract：:One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

journal_title：Hematological oncology

authors： Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

更新日期：1993-01-01 00:00:00

abstract：:Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

journal_title：Hematological oncology

authors： Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

更新日期：1994-01-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...

journal_title：Hematological oncology

authors： Le Bris Y,Magrangeas F,Moreau A,Chiron D,Guérin-Charbonnel C,Theisen O,Pichon O,Canioni D,Burroni B,Maisonneuve H,Thieblemont C,Oberic L,Gyan E,Pellat-Deceunynck C,Hermine O,Delfau-Larue MH,Tessoulin B,Béné MC,Minviel

更新日期：2020-10-01 00:00:00

abstract：:This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

journal_title：Hematological oncology

authors： Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

更新日期：2014-06-01 00:00:00

abstract：:Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

journal_title：Hematological oncology

authors： Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

更新日期：1990-03-01 00:00:00

abstract：:Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

journal_title：Hematological oncology

authors： Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

更新日期：2020-10-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

journal_title：Hematological oncology

authors： Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

更新日期：2017-12-01 00:00:00

abstract：:Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

journal_title：Hematological oncology

authors： Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

更新日期：2018-04-01 00:00:00

abstract：:We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...

journal_title：Hematological oncology

authors： Broccia G,Deplano W,Dessalvi P,Giannico B,Luxi G,Chessa E,Murru A

更新日期：2004-09-01 00:00:00

abstract：:The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but ma...

journal_title：Hematological oncology

authors： McMullin MF

更新日期：2007-06-01 00:00:00

abstract：:This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

journal_title：Hematological oncology

authors： Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

更新日期：2008-12-01 00:00:00

abstract：:The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...

journal_title：Hematological oncology

authors： Albano D,Bruno A,Patti C,Micci G,Midiri M,Tarella C,Galia M

更新日期：2020-02-01 00:00:00

abstract：:Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

journal_title：Hematological oncology

authors： Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

更新日期：2008-03-01 00:00:00

abstract：:This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

journal_title：Hematological oncology

authors： Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

更新日期：2018-10-01 00:00:00

abstract：:Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

journal_title：Hematological oncology

authors： Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

更新日期：1989-11-01 00:00:00

abstract：:The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between ly...

journal_title：Hematological oncology

authors： Mancuso S,Carlisi M,Napolitano M,Siragusa S

更新日期：2018-02-27 00:00:00

abstract：:One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...

journal_title：Hematological oncology

authors： Jain NC,Cox C,Bennett JM

更新日期：1987-07-01 00:00:00

abstract：:There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

journal_title：Hematological oncology

authors： Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

更新日期：2013-03-01 00:00:00

abstract：:Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

journal_title：Hematological oncology

authors： Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

更新日期：2020-10-01 00:00:00

abstract：:Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...

journal_title：Hematological oncology

authors： Krashin E,Ellis M,Cohen K,Viner M,Neumark E,Rashid G,Ashur-Fabian O

更新日期：2018-04-01 00:00:00

abstract：:B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

journal_title：Hematological oncology

authors： Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

更新日期：2008-12-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

journal_title：Hematological oncology

authors： Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

更新日期：2012-09-01 00:00:00

abstract：:We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

journal_title：Hematological oncology

authors： Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

更新日期：1994-05-01 00:00:00

abstract：:Intravascular lymphoma (IVL) is an extremely rare form of non-Hodgkin lymphoma characterized by almost exclusive growth of neoplastic lymphocytes within blood vessel lumen. IVL is morphologically characterized in most instances by large cells with B-cell lineage. IVL is an aggressive and usually disseminated disease t...

journal_title：Hematological oncology

authors： Ponzoni M,Ferreri AJ

更新日期：2006-09-01 00:00:00

abstract：:This report summarizes a closed workshop cosponsored by the American Association for Cancer Research, the European School of Oncology, and the 15th-International Conference on Malignant Lymphoma to discuss critical open questions on liquid biopsy in lymphoid malignancies, develops a roadmap for their analytical and cl...

journal_title：Hematological oncology

authors： Rossi D,Kurtz DM,Roschewski M,Cavalli F,Zucca E,Wilson WH

更新日期：2020-02-01 00:00:00